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FACS analysis together with PIPLC treatment was applied to PI-anchoring antigens uch as DAF (decay-accerelating factor, CDSS), IF5 antigen 
(CD59), CD14 and CD16 on the cell surfaces of blood cells from a normal adult and a male patient with paroxysmal nocturnal hemoglubinuria 
(PNH). Through the extensive analysis, this patient proved to be completely defective in lF5 antigen, a newly found complement-regulatory protein, 
on all the blood cells tested. In normal blood cells such as lymphocytes, monocytes and granulocytes, lF5 antigen was expressed as one of PI- 
anchoring proteins. In contrast o most of PNH patients, this patient reserved DAF, CD14 and CD16 at normal levels in his erythrocytes, monocy- 
tes and granulocytes. Also, there were no significant differences between the normal adult and the patient in the activities of erythrocyte acetylchol- 
inesterase and granulocyte alkaline phosphatase which were also known to be PI-anchoring enzymes. Thus, deficiency of lF5 antigen must be 
deeply related to the clinical symptoms of PNH in this patient. 
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1. INTRODUCTION 
Paroxysmal nocturnal hemoglobinuria (PNH) has 
been known as an acquired clonal disorder of the bone- 
marrow stem cells that results in defects of the 
erythroid, monomyeloid and platelet cell-lineages. 
Recently, several authors [l-6] reported the expression 
of individual PI (phosphatidylinositol)-anchoring pro- 
teins to be markedly low on the surface of blood cells 
from the PNH patients. In this study, we estimated the 
expression of four PI-glycan-anchored antigens uch as 
DAF [7,8], CD14 [9], CD16 [lO,ll] and lF5 antigen 
[12] in granulocytes, lymphocytes, monocytes and 
erythrocytes from a male PNH patient, in comparison 
with those cells from a normal adult. DAF (decay ac- 
celerating factor, CD55) is a membrane protein of 
molecular mass 70 kDa with complement-regulatory 
activity, inhibiting the assembly of complement and ac- 
celerates the natural decay of the classical and alter- 
native pathway C3 convertase. CD14 is a protein an- 
tigen on human monocytes as reported by Haziot et al. 
[9]. CD16, FcRIII receptor present in 135000 sites on 
neutrophils, is characterized as one of the Fc receptors 
which bind IgG-containing immune complexes, leading 
to phagocytosis of the complex and activation of the 
neutrophil. lF5 antigen (CD59) discovered by Okada et 
al. [12], is a membrane glycoprotein of 20 kDa which 
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regulates the complement-activating reaction, i.e. 
hemolysis of neuraminidase-treated human erythro- 
cytes via the alternative pathway. In spite of different 
sensitivity, these protein antigens have been shown to 
be released from blood cells by the action of PIPLC 
[7-121. 
We also assayed the activity of acetylcholinesterase 
on red blood cells (RBC) and alkaline phosphatase on 
white blood cells (WBC). These enzymes were also re- 
ported to be PI-anchoring proteins [13-161. 
2. MATERIALS AND METHODS 
2.1. Cell preparation 
Heparinated fresh blood was centrifuged at 700 x g for 10 min. 
After removal of plasma and buffy coat, erythrocytes were washed 
three times with phosphate-buffered saline (PBS). White blood cells 
(lymphocytes, granulocytes and monocytes) were separated from 
fresh heparinated blood by centrifugation. The contaminating 
erythrocytes were removed by hypotonic lysis. 
2.2. PIPLC treatment 
Phosphatidylinositol-specific phospholipase C (PIPLC) was 
purified from the culture broth of Bacillus thuringiensis IAM 12077 
according to the isolation procedures described by Ikezawa et al. [17]. 
Washed RBC (red blood cells) and WBC (white blood cells) were 
suspended in 0.25 M sucrose containing 10 mM Tris-HCl buffer (pH 
7.4) at concentrations of 10’ and 10’ cells/ml, respectively. These cell 
suspensions (each 1 ml) were mixed with 1 U (for RBC) or 2 U (for 
WBC) of PIPLC and incubated for 20 min at 37°C. After incubation, 
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the suspension was centrifuged at 700 x g 10 min. Precipitated cells 
were then washed two times with PBS, and subjected to FACS 
analysis. The resulting supernatants were then centrifuged at 
40000 x g for 20 min, and subjected to enzyme analysis. 
3. RESULTS AND DISCUSSION 
2.3. FACS analysis 
PBS (25 ~1) containing lo6 cells were treated with 0.3-2.5 pg of 
corresponding antibodies in microtiter wells. Flow cytometric analysis 
was carried out with a Coulter Epics profile for ‘single-color’ analysis 
and a FACScan (Becton Dickinson) for ‘two-color’ analysis. In some 
groups, control cells were analyzed in the presence of rat or rabbit IgG 
immunoreagents for calculating the cytophilic binding. 
3.1. Expression of DAF on the blood ceils from a 
normal adult and a PNHpatient and sensitivity of 
DAF to PIPLC 
DAF on normal RBC, granulocytes and monocytes 
2.4. Enzyme assays 
The activities of PIPLC and alkaline phosphatase were determined 
according to the method described by Taguchi et al. [18]. The activity 
of acetylcholinesterase was determined by the method of Ellman et al. 
1191. 
2.5. Antibodies 
Anti-CD16 IgG(NKP-15) was purchased from Becton-Dickinson 
Co., and anti-CD14 IgG(MY4) and NKH-1 was from Coulter Co. 
Anti-DAF IgG was a gift from Dr T. Fujita. lF5 IgG was kindly sup- 
plied by Dr N. Okada. 
2.6. Estimation of protein 
was expressed as a single population, but that on lym- 
phocytes as multiple populations. By PIPLC treatment, 
DAF on RBC was reduced not more than lo%, as 
shown previously by Davitz et al. [7] and Medof et al. 
[S]. However, a significant amount of DAF was re- 
moved from the surfaces of granulocytes (32Vo), mono- 
cytes (48%) and lymphocytes (75%). Therefore, DAF 
generally exists as a PI-anchoring form in several blood 
cells from the normal adult, although it is not easily 
solubilized from RBC by PIPLC. Concerning to this 
point, Roberts et al. [21] reported that the resistance of 
acetylcholinesterase on human RBC to PIPLC treat- 
ment is due to the existence of an additional fatty acyl 
chain on the inositol ring which blocks the action of 
PIPLC. 
Protein contents were determined according to the method of DAF expression of this PNH patient was not essen- 
Lowry et al. [20] with bovine serum albumin as a standard. tially different from that of the normal adult on RBC, 
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Fig. 1. Comparative analysis of DAF expression on blood cells of the normal donor and a PNH patient. Cells were reacted with monoclonal mouse 
anti-DAF IgG(l), then stained with FITC-conjugated rabbit anti-mouse IgG. Control cells were directly stained with FITC-conjugated nonimmune 
mouse IgG(1) of FITC-conjugated rabbit anti-mouse IgG. (-_), Control; (-), the normal donor; (’ l l l l ), the PNH patient. 
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lymphocytes, monocytes and granulocytes (fig. 1). Also 
in the patient cells, the extents of DAF solubilization 
with PIPLC is similar to those in normal cells (data not 
shown), According to Nicholson-Weller et al, fl,4], 
Kinoshita et al. [5], DAF deficiency was found in 
almost all cases of PNH patients they observed. In fact, 
DAF deficiency itself has been considered to be an 
essential index in the diagnosis of PNH. According to 
Ninomiya et al. [22], however, RBC from two of eight 
patients which they examined contained DAF at normal 
levels. Among the ten PNH patients which we are exa- 
maining and will report elsewhere, this patient is also 
unique in his full expression of DAF on RBC, as com- 
pared with other patients. 
3.2. Expression of IF5 antigen and its sensitivity to 
PIPLC 
IF5 antigen on normal blood cells was expressed as a 
single population in RBC, monocytes and granulocytes, 
except in lymphocytes (fig.2). By PIPLC treatment, the 
content of lF5 antigen was significantly decreased in 
granuloc~es (55%), monocles (54%) and lymphocytes 
(80%). Like DAF, lF5 antigen were not released from 
RBC by PIPLC not more than 15%, although this an- 
tigen was demonstrated by Okada et al. [12] to be an- 
chored with PI to RBC membrane. On the other hand, 
IF5 antigen was completely defective in all kind of pa- 
tient blood cells tested, as shown in fig.2. Therefore, 
clinical symptoms of PNH in this patient, such as 
sucrose hemolysis and complement activated hem~lysis 
in Ham test, must be related to lF5 antigen deficiency. 
Compiement~regulatory protein antigens similar to 
DAF and lF5 antigen have been shown as membrane 
cofactor protein [23], homologous restriction factor 
(HRF) [24], C8-binding protein [25] and P-18 protein 
1261. Among these proteins, P-18 protein seems to be 
immunologically identical to IF5 antigen (personal 
communication). 
3.3, Expression of Cl224 and Cl316 a~tjg~~ and their 
sensitivity to PIPLC 
Fig.3 shows expression of CD16 in granulocytes and 
lymphocytes, and CD14 in monocytes from a normal 
adult and the PNH patient, and sensitivity of these an- 
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Fig.2. Comparative analysis of lF5 antigen expression on blood cells of the normal donor and the PNH patient. PlPLC-treated and -untreated 
cells were reacted with monoclonal mouse lF5 IgGfl), then stained with FITC-conjugate rabbit anti-mouse IgG. Control cells were treated in 
the same way as in fig.1. (--- ), Control; (-), the normal donor (PIPLC-untreated); ( l l 0 l l ), the normal donor (PIPLC-treated); (-----), 
the PNH patient (PIPLC-untreated). 
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Fig.3. FACS analysis of CD16 and CD14 expression on blood cells of the normal donor and the PNH patient. PIPLC-treated and -untreated cells 
were stained with FITC-conjugated mouse anti-CD16 IgG(1) or FITC-conjugated mouse anti-CD14 IgG(2). Control cells were directly reacted 
with FITC-conjugated mouse nonimmune IgG(1) or FITC-conjugated mouse nonimmune IgG(2b). (-), Control; (-), PIPLC-untreated; 
(* l l l l ), PIPLC-treated. 
tigens to PIPLC. CD14 was exclusively expressed on 
monocytes from the patient as well as the normal adult. 
Similarly, CD16 was mainly expressed on granulocytes 
from these two persons. CD14 and CD16 were effec- 
tively released by PIPLC from monocytes (20%) and 
granulocytes (5OOro), respectively. In the present study, 
however, an interesting subpopulation containing 
PIPLC-insensitive CD16 was found in normal and 
PNH lymphocytes. This CD16 in PNH lymphocytes 
was expressed at very low level. This subpopulation 
proved to be the population of NK cells, since it was 
double-stained with monoclonal antibody NKH-1 and 
anti-CD16 IgG. However, our recent study (will be 
published later) suggests that low expression of CD16 
on NK cells observed in this patient is not a common 
feature of PNH patients; only two out of ten PNH pa- 
tients show low expression of CD16 on NK cells. 
Recently, Lanier et al. [27] reported that CD16 was ex- 
pressed on NK cells as well as leukocytes, and that 
molecular size of CD16 on NK cells were slightly dif- 
ferent from that on leukocytes. These results suggest 
the possibility that CD16 on NK cells is not to be a PI- 
anchoring protein, but to be anchored to the membrane 
by a C-terminal, hydrophobic peptide tail. 
3.4. Expression of PI-anchoring enzymes in blood cells 
There were no significant differences between the 
normal adult and the patient in the activity levels of 
acetylcholinesterase on RBC ghosts and of alkaline 
phosphatase on white blood cells (mainly on granulo- 
cytes). 
Recently, growing interest has been directed to physi- 
ological significance of PI-anchoring proteins. For in- 
stance, expression of these proteins on blood cells seems 
to be directly related to the cell differentiation. In fact, 
decrease or deficiency in PI-anchoring proteins in PNH 
patients suggests that PNH is caused by clonal disorder 
or irregular differentiation in these cells. 
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Appendix: During preparation of this paper Ravetech and Perussia 
[28] have reported that CD16 observed in NK cell is resistant to 
PIPLC treatment, encoded in a different gene from that of granulo- 
cyte and expressed as a non PI-anchoring form. 
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